NCT01072578View on ClinicalTrials.gov

A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood Glucose

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

Healthy Volunteers

Interventions

DRUG

Dapagliflozin

Dapagliflozin tablets 5 mg, Oral Twice daily dose for 5 days (total daily dose 10 mg)

DRUG

Dapagliflozin

Dapagliflozin tablets, 10 mg, Oral, once daily dose for 5 days

Trial Locations (1)

Unknown

Research Site, Berlin

Sponsors

Lead Sponsor

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AstraZeneca

INDUSTRY